Intranasal COVID-19 Vaccine Shows High Seroresponse

A Phase I randomized, double-blind, placebo-controlled dose-escalation study in healthy adults, called CDX-CoV-001, has found Codagenix’s intranasal COVID-19 vaccine candidate, CoviLiv, showed the vaccine had a high seroresponse rate and induced mucosal immunity in volunteers not previously vaccinated or infected.

Moderna’s Influenza-COVID-19 Vaccine Demonstrates Immunogenecity

Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.

Study Finds Adult Vaccines Potentially Protect Against Alzheimer’s

Study Finds Adult Vaccines Potentially Protect Against Alzheimer’s

A new study conducted at the University of Texas Health Science Center at Houston found that people who received shingles and pneumonia vaccines — along with tetanus and diphtheria — had as much as a 30 percent reduced risk of developing Alzheimer’s the most common type of dementia.

FDA Approves Pfizer’s ABRYSVO Vaccine for the Prevention of RSV

FDA Approves Pfizer’s ABRYSVO Vaccine for the Prevention of RSV

Pfizer’s ABRYSVO, a respiratory syncytial virus (RSV) vaccine, has been approved by the U.S. Food and Drug Administration for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to 6 months of age by active immunization of pregnant women at 32 through 36 weeks gestational age.

Inverse Vaccine May Reverse Autoimmune Diseases

Researchers from the Pritzker School of Molecular Engineering at the University of Chicago have developed a new type of vaccine called an “inverse vaccine that completely reversed autoimmune diseases without fully shutting down the rest of the immune system.